Site is Being Upgraded

Molecular therapy for ageing-associated diseases and Lifespan extension: Rolipram, an experimental drug used in the treatment of depression and others, increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 16/February/2018, 7.01 am

Vitamin-based therapy for glucose homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Sulforaphane increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 16/February/2018, 6.48 am
February 16, 2018
Laminar shear stress-based therapy for autoimmune diabetes (TIDM): Laminar shear stress increases PD-L1 expression, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 16/February/2018, 7.13 am
February 16, 2018
Show all

Introduction: What they say

A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, New South Wales 2052, Australia shows that “A conserved NAD+ binding pocket that regulates protein-protein interactions during aging.” This research paper was published, in the 24 March 2017 issue of the journal “Science [One of the best research journals in Science with an I.F of 34+], by Prof. David A. Sinclair, Jun Li and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Molecular therapy for ageing-associated diseases and Lifespan extension: Rolipram, an experimental drug used in the treatment of depression and others, increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene


What is known?

Prof. David A. Sinclair’s research team has recently shown that: (a) increased levels of NAD+ (found in non-aged tissues) inhibits the interaction the between DBC1 (deleted in breast cancer 1) and PARP1 [poly(adenosine diphosphate–ribose) polymerase]; and promotes DNA repair; (b) decreased levels of NAD+ (found in aged tissues) promotes the interaction between DBC1 and PARP1 and inhibits DNA repair; (c) aged cells/tissues that are low in NAD+ are radiation-sensitive, cancer-prone and prone to accelerated ageing; and (d) ageing-associated diseases can be reversed by increasing the concentration of NAD+ in ageing tissues, suggesting that ageing-associated diseases, in part, can be reversed by NAD+ supplementation in older animals.


From research findings to therapeutic opportunity:

This study suggests, for the first time, a small molecule-based therapy for aging-associated diseases; and for extending lifespan.

Rolipram, by increasing the expression of its target gene, it may increase the levels of NAMPT and NMN/NAD+. Thereby, it may: (1) increase plasma NMN levels and tissue NAD+ availability; (2) inhibit the interaction between DBC1 and PARP1; (3) augment PARP1’s DNA repair activity; (4) protect against radiation; (5) protect against cancer; and (6) prevent age-associated gene expression pattern and accelerated ageing.

Thus, pharmacological formulations encompassing “Rolipram or its analogues, either alone or in combination with other nutritional compounds,” may be used to suppress age-associated overall physiological decline and improve health/life span.[easy_payment currency=”USD”]

Figure1. Rolipram may act as an anti-ageing and a longevity-promoting compound.  Rolipram, by increasing NAD+ levels, may suppress ageing-associated overall physiological decline, ageing-associated diseases and improve health/life-span

Figure 2. The chemical structure of Rolipram


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How   Rolipram  increases the levels of NMN/NAD to inhibit interaction between DBC1 and PARP1 and to promote DNA repair activity

Amount: $300#

* Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Citation: Boominathan, L., Molecular therapy for ageing-associated diseases and Lifespan extension: Rolipram, an experimental drug used in the treatment of depression and others, increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 16/February/2018, 7.01 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite us, kindly drop us a line

Comments are closed.